Q2 2024 saw 19% sales growth and 13% EBITA growth, led by strong results in Assistive Tech and MedTech, while Specialty Pharma declined due to UK price pressure. Cash flow and balance sheet remain strong, supporting ongoing M&A activity.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.